We transcend borders, time zones, and especially the status quo to develop therapies that are more accessible to people around the world.

Learn More

Putting Patients First

We offer resources to help patients and their loved ones navigate some of the complex challenges that follow the words, “You have cancer.”

Learn More
elder_women

Science-Based, Passion-Driven

We are advancing an innovative, high-value product portfolio for patients globally.

Learn More
doctor_and_patient

Passion with Purpose

We work to benefit patients wherever they live by uniting worldwide talent and resources with our vision.

Learn More
people_walking

BeiGene News

November 22, 2022

BeiGene to Present Final PFS Results from ALPINE Trial Demonstrating Superior PFS for BRUKINSA® Versus IMBRUVICA® in Late-Breaking Oral Session at ASH 2022

Read more

November 17, 2022

BeiGene Receives European Commission Approval for BRUKINSA® (zanubrutinib) for the Treatment of Adults with Chronic Lymphocytic Leukemia (CLL)

Read more

November 15, 2022

BeiGene Launches Talk About It Program to Elevate the Importance of Addressing Mental Health during Cancer Care

Read more

November 10, 2022

BeiGene Announces Brazil Approvals for BRUKINSA® As a Treatment for Rare Blood Cancers

Read more

November 9, 2022

BeiGene Reports Third Quarter 2022 Financial Results

Read more

November 4, 2022

BeiGene to Present at Upcoming Investor Conferences

Read more